EMA/HMA/ECA: List of Active Substances defined to prevent supply bottlenecks
Recommendation

10/11 February 2026
Risk analysis, preventive measures and incident management
As part of the measurements against supply shortages in the pharmaceutical sector, the first version of the "Union list of critical medicines" and further information was published on the EMA website at the end of last year. This list contains more than 200 active substances that are considered critical in the event of a supply shortage and whose shortage must be avoided at all costs. These substances were chosen by all EU member states from a selection of 600 substances, and it is already clear that the list will be expanded in 2024. Currently, the substances on the list are categorised according to their "ATC description" (Anatomical Therapeutic Chemical code) and belong to a wide range of active substances including vaccines.
The Q&A document "Questions and answers on the Union list of critical medicines" provides further information on the list of active substances. In 19 questions and answers, it explains, for example, what obligations the list entails for marketing authorisation holders, what significance the list has for patients, suppliers or doctors and how the list should be used and understood.
Both the "Union list of critical medicines" and the "Questions and answers on the Union list of critical medicines" can be viewed on the EMA website.
Related GMP News
28.01.2026IPEC: Revised REACH Guide for Excipients
28.01.2026EDQM: New General Chapter 'Quality of Data' available
21.01.2026FDA Warning Letter: Q-Unit failed to document API release
14.01.2026Testing for ethylene glycol, diethylene glycol and methanol – a hot topic during FDA inspections
14.01.2026APIC: Update to the Data Integrity FAQs


